The Week In Cannabis: FDA, CDC, Delta-8 THC, WADA, Canopy, Sundial, Canada, LatAm And More
Below is a recap of the main news related to the cannabis industry and markets for the week of September 13, 2021.
Contents
AFC Gamma’s Stock Slightly Down After Announcing $30M Expansion Of Nature’s Medicines Credit Facility
Cannabis-focused mortgage real estate finance enterprise AFC Gamma, Inc. (NASDAQ: AFCG) said Monday it has bolstered $62.5 million in funding for Devi Holdings Inc., which is doing business as Nature’s Medicines.
The Week In Cannabis: $2B+ In M&A And Financings, Hexo, Terrascend, Gage, The DEA, NY, Panama And More
Below is a recap of the main news related to the cannabis industry and markets for the week of August 30, 2021.
Contents
AFC Gamma Lends BeLeaf Medical $23M To Help Co. Expand Missouri Market
AFC Gamma, Inc. (NASDAQ: AFCG) announced Tuesday that it has provided a credit facility of $23 million to BeLeaf Medical, LLC, a single-state Missouri operator.
Jefferies Initiates Coverage On AFC Gamma with Buy Rating, Announces Price Target of $24
Jefferies analyst John Hecht initiates coverage on AFC Gamma (NASDAQ:AFCG) with a Buy rating and announces Price Target of $24.
Finding Principal Safety, Capital Appreciation With Real Estate Investments
Commercial real estate, given a multiyear boom in demand, may offer investor portfolios diversity and income.
Cowen & Co. Initiates Coverage On AFC Gamma with Outperform Rating, Announces Price Target of $27
Cowen & Co. initiates coverage on AFC Gamma (NASDAQ:AFCG) with a Outperform rating and announces Price Target of $27.
AFC Gamma Q2 EPS $0.43 Down From $0.87 YoY
AFC Gamma (NASDAQ:AFCG) reported quarterly earnings of $0.43 per share. This is a 50.57 percent decrease over earnings of $0.87 per share from the same period last year.